Quality Management in Pharma: Johnson & Johnson vs. Mylan
This paper compares the quality management processes of two pharmaceutical companies — Johnson & Johnson, a global industry leader, and Mylan, a domestic generic drug producer. Focusing on traceability as a core quality management function, the analysis examines how each company's supply chain strategies, supplier auditing practices, and regulatory compliance frameworks differ based on their respective business models. The paper also explores how traceability contributes to competitive advantage and brand reputation, and argues that quality management is not merely a compliance requirement but a strategic priority for both global and domestic pharmaceutical manufacturers.
- Introduction: Overview of two firms and analytical framework
- Traceability Processes at Johnson & Johnson and Mylan: Operational traceability differences including RFID and audits
- How Traceability Contributes to Greater Competitiveness: Traceability as strategic and competitive advantage
- Quality Management and Market Position: Brand value and reputation tied to quality systems
- Conclusion: Strategic importance of pharmaceutical quality management
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Uses a concrete side-by-side comparison of two real companies to ground abstract quality management concepts in industry practice.
- Connects operational details (RFID adoption, Six Sigma, supplier audits) to broader strategic outcomes like brand reputation and competitive positioning.
- Anchors claims with peer-reviewed citations from supply chain and health care quality journals, lending credibility to the analysis.
Key academic technique demonstrated
The paper demonstrates comparative analysis as a structured academic technique: it establishes a shared framework (traceability) and then systematically applies it to two organizations with different business models, scale, and strategic priorities. This approach allows the author to highlight meaningful differences rather than simply listing facts about each company in isolation.
Structure breakdown
The paper opens with an introduction that identifies both companies and the analytical lens (traceability and quality management). A dedicated traceability section — supported by a referenced workflow diagram — examines operational differences, including RFID adoption and supplier auditing depth. A subsequent section elevates the discussion to competitive strategy, arguing that traceability is more than compliance. The final substantive section ties quality management directly to brand value and market position for each firm, before a brief closing argument.
Introduction
Comparing the quality management processes of global and domestic pharmaceutical organizations yields significantly different results. The two companies included in this analysis are Johnson & Johnson, a global leader in the pharmaceutical industry, and Mylan, a domestic producer of generic drugs. Supplier quality management strategies at each company follow a comparable framework that includes reverse logistics, which enables traceability (Kumar, Dieveney, & Dieveney, 2009). Both companies are also continually evaluated by the Food & Drug Administration, which has the authority of the federal government to launch on-site audits, unannounced, any day of the year (Murray & McAdam, 2007). Quality management and compliance are critical for risk reduction — not just from a governance standpoint but from an operating expense reduction standpoint as well (Fiscus, 2009). The process of traceability, which is critical for quality management and compliance, is compared between these two firms.
References
Connolly, C. (2007). Sensor trends in processing and packaging of foods and pharmaceuticals. Sensor Review, 27(2), 103.
Enderwick, P. (2009). Avoiding quality fade in Chinese global supply chains: Designing appropriate governance structures. Business Process Management Journal, 15(6), 876–894.
Fiscus, P. (2009). Global risks for drug manufacturers. Risk Management, 56(3), 50–54.
Hook, B. (2010, March). Traceability and scalability: A new era in healthcare logistics. Supply Chain Europe, 19(2), 18–19.
Kumar, S., Dieveney, E., & Dieveney, A. (2009). Reverse logistic process control measures for the pharmaceutical industry supply chain. International Journal of Productivity and Performance Management, 58(2), 188–204.
Murray, E., & McAdam, R. (2007). A comparative analysis of quality management standards for contract research organisations in clinical trials. International Journal of Health Care Quality Assurance, 20(1), 16–33.
Schnoll, L. (2008). Ensuring supplier quality. Quality Progress, 41(8), 64–66.
Create your account
Always verify citation format against your institution’s current style guide requirements.